Bal Pharma Ltd.

117.55 -0.95 ▼-0.8%

22 February 2024, 04:01:00 PM
Volume: 8,281

Company Profile

Sector Healthcare Sector Icon Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Industry Icon Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.balpharma.com
Market Cap 185.83 Cr.
Enterprise Value(EV) 318.51 Cr. 2023-09
Financial Indicators
Earnings per share (EPS) 2.23 Trailing Twelve Months Ending 2023-12
Price-Earning Ratio (PE) 52.81 Trailing Twelve Months Ending 2023-12
Industry PE 41.89 Trailing Twelve Months Ending 2023-12
Book Value / Share 40.63 Trailing Twelve Months Ending 2023-12
Price to Book Value 2.89 Calculated using Price: 117.55
Dividend Yield 0.85 Period Ending 2023-03
No. of Shares Subscribed 1.58 Cr. 15,808,372 Shares
FaceValue 10
About Bal Pharma Ltd.
Bal Pharma, incorporated in 1987 is engaged in the business interest in area of manufacturing API, finished formulations, ayurvedic and research and development. It is one of the leading Indian pharmaceutical companies that focuses on prescription drugs, generic, OTC products, intravenous infusion and bulk actives.

Bal Pharma Ltd. Delivery

Delivered Qty
Traded Qty

Bal Pharma Ltd. Performance

1 Day
-0.80%
1 Week
+2.98%
1 Month
-1.18%
3 Month
+9.67%
6 Month
+29.72%
1 Year
+53.76%
2 Year
+12.49%
5 Year
+75.97%
10 Year
+267.92%

Bal Pharma Ltd. Fundamental Ratios

9 years 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03 2022-03 2023-03
Return on Equity (%) 7 0.49 -0.69 0.59 3.27 -21.65 8.97 10.34 4.31
Return on Capital Employed (%) 10.88 7.35 7.59 7.45 6.88 -0.44 9.72 12.33 9.56
Return on Assets (%) 2.23 0.14 -0.18 0.15 0.83 -5.16 1.97 2.28 0.92

Bal Pharma Ltd. Balance Sheet

Particulars 10 years 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr. 2023-09* Rs. Cr.
Shh. Funds 55 55 62 65 67 52 54 59 64 63
Non Curr. Liab. 16 45 30 46 38 34 34 36 38 36
Curr. Liab. 92 111 143 154 163 159 153 166 209 229
Minority Int. 0 0 -2 -5 -6 -7 0 0 0 0
Equity & Liab. 164 211 233 260 261 238 240 261 311 328
Non Curr. Assets 59 68 69 75 78 81 76 76 83 83
Curr. Assets 105 143 165 185 183 157 164 185 228 244
Misc. Exp. not W/O
Total Assets 164 211 233 260 261 238 240 261 311 328

Bal Pharma Ltd. Profit and Loss

Particulars 10 years 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr. 2023-12 Rs. Cr. TTM
Net Sales 187 198 229 209 225 171 251 281 304 327
Other Income 1 1 3 2 1 2 1 5 1 1
Total Income 188 200 232 211 226 173 252 286 305 328
Total Expenditure -170 -183 -214 -192 -207 -166 -226 -257 -279 -297
PBIDT 18 16 18 19 19 7 26 29 26 31
Interest -7 -6 -8 -9 -13 -13 -12 -11 -12 -15
Depreciation -7 -7 -6 -7 -6 -8 -10 -9 -9 -10
Taxation -1 -2 -3 -3 2 1 1 -3 -2 -2
Exceptional Items
PAT 4 0 0 0 2 -13 5 6 3 4
Minority Interest 0 1 2 2 2 1 0 0 0 0
Share Associate
Other Related Items
Consolidated Net Profit 4 1 2 3 4 -12 5 6 3 4
Adjusted EPS 3 1 1 2 3 -9 3 4 2 2

Bal Pharma Ltd. Cash Flow

Particulars 10 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr.
Cash Fr. Operatn. 13 15 -19 6 1 8 23 22 27 -2
Cash Fr. Inv. -7 -5 -14 -8 -4 -8 -5 -6 -9 -22
Cash Fr. Finan. -8 -7 32 -6 4 0 -20 -17 -17 24
Net Change -2 2 -1 -8 1 0 -1 0 0 0
Cash & Cash Eqvt 3 5 5 -25 3 2 1 1 1 1

Bal Pharma Ltd. Shareholding Pattern

9 Qtrs 2021-12 (%) 2022-03 (%) 2022-06 (%) 2022-09 (%) 2022-12 (%) 2023-03 (%) 2023-06 (%) 2023-09 (%) 2023-12 (%)
Promoter 49.57 49.57 52.00 52.00 51.61 51.61 51.61 51.61 51.23
Public 50.43 50.43 48.00 48.00 48.39 48.39 48.39 48.39 48.77
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Bal Pharma Ltd. Announcements

Wed, 14 Feb 2024
Announcement under Regulation 30 (LODR)-Newspaper Publication
We are submitting to the exchanges copies of the newspaper advertisements of abridged standalone and consolidated financial results of the Company for the quarter and nine months ended 31.12.2023 announced by the Company on 12.02.2024 and published in Financial Express ( English) and Sanjayvani ( Kannada ) on 13.02.2024.
Mon, 12 Feb 2024
Unaudited Financial Results For The Quarter Ended 31.12.2023.
Unaudited standalone and consolidated Financial results for the quarter and 9 months ended 31.12.2023.
Mon, 12 Feb 2024
Board Meeting Outcome for Unaudited Financial Results For The Quarter And 9 Months Ended 31.12.2023.
1. Taken on record and approved the Un-Audited Standalone and Consolidated Financial Results of the Company for the Quarter and 9 Months ended 31.12.2023. A copy of the approved financial results together with Limited Review Reports issued by the statutory auditors of the company with unmodified opinion is enclosed with this intimation.2. The Board has considered and acknowledged the receipt of letter of allotment from KIADB allotting 5 acres of land to the company at Kadechur KIADB industrial area Yadgiri Karnataka. The proposed project for setting up of the API and Intermediaries manufacturing facility at the above said industrial are was approved at the State Level Single Window Clearance Committee Government of Karnataka.

Bal Pharma Ltd. Technical Scans

Thu, 22 Feb 2024
High Delivery Percentage High Delivery Percentage
Higher Delivery Quantity Higher Delivery Quantity
Higher Delivery Quantity and Percentage Higher Delivery Quantity and Percentage
Opening at High Opening at High
Closing Below Previous Low Closing Below Previous Low

Bal Pharma Ltd. Related Stocks

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 373,756.40 1,553.75 +0.7%
Cipla Ltd. 117,370.75 1,453.75 +0.4%
Dr. Reddy's Laboratories Ltd. 106,155.83 6,344.05 -0.1%
Apollo Hospitals Enterprise Ltd. 97,309.86 6,766.05 +0.1%
Divi's Laboratories Ltd. 96,809.75 3,642.80 -0.2%
Zydus Lifesciences Ltd. 91,584.23 904.80 +1.3%
Torrent Pharmaceuticals Ltd. 88,295.34 2,611.70 +0.4%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-12 41.97 1,553.75 +0.7%
Cipla Ltd. Consolidated 2023-12 31.65 1,453.75 +0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-12 20.30 6,344.05 -0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-12 123.28 6,766.05 +0.1%
Divi's Laboratories Ltd. Consolidated 2023-12 70.00 3,642.80 -0.2%
Zydus Lifesciences Ltd. Consolidated 2023-12 30.80 904.80 +1.3%
Torrent Pharmaceuticals Ltd. Consolidated 2023-12 59.10 2,611.70 +0.4%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-12 5.99 1,553.75 +0.7%
Cipla Ltd. Consolidated 2023-12 4.53 1,453.75 +0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-12 3.95 6,344.05 -0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-12 14.41 6,766.05 +0.1%
Divi's Laboratories Ltd. Consolidated 2023-12 7.43 3,642.80 -0.2%
Zydus Lifesciences Ltd. Consolidated 2023-12 4.71 904.80 +1.3%
Torrent Pharmaceuticals Ltd. Consolidated 2023-12 12.35 2,611.70 +0.4%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 0.11 1,553.75 +0.7%
Cipla Ltd. Consolidated 2023-03 0.02 1,453.75 +0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 0.06 6,344.05 -0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 0.44 6,766.05 +0.1%
Divi's Laboratories Ltd. Consolidated 2023-03 0.00 3,642.80 -0.2%
Zydus Lifesciences Ltd. Consolidated 2023-03 0.07 904.80 +1.3%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 0.85 2,611.70 +0.4%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 16.46 1,553.75 +0.7%
Cipla Ltd. Consolidated 2023-03 12.85 1,453.75 +0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 21.36 6,344.05 -0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 15.16 6,766.05 +0.1%
Divi's Laboratories Ltd. Consolidated 2023-03 14.89 3,642.80 -0.2%
Zydus Lifesciences Ltd. Consolidated 2023-03 11.60 904.80 +1.3%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 20.50 2,611.70 +0.4%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 16.46 1,553.75 +0.7%
Cipla Ltd. Consolidated 2023-03 12.85 1,453.75 +0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 21.36 6,344.05 -0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 15.16 6,766.05 +0.1%
Divi's Laboratories Ltd. Consolidated 2023-03 14.89 3,642.80 -0.2%
Zydus Lifesciences Ltd. Consolidated 2023-03 11.60 904.80 +1.3%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 20.50 2,611.70 +0.4%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 43,885.68 1,553.75 +0.7%
Cipla Ltd. Consolidated 2023-03 22,753.12 1,453.75 +0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 24,669.70 6,344.05 -0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 16,612.50 6,766.05 +0.1%
Divi's Laboratories Ltd. Consolidated 2023-03 7,767.51 3,642.80 -0.2%
Zydus Lifesciences Ltd. Consolidated 2023-03 17,237.40 904.80 +1.3%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 9,620.15 2,611.70 +0.4%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 8,560.84 1,553.75 +0.7%
Cipla Ltd. Consolidated 2023-03 2,835.49 1,453.75 +0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 4,507.30 6,344.05 -0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 887.50 6,766.05 +0.1%
Divi's Laboratories Ltd. Consolidated 2023-03 1,823.38 3,642.80 -0.2%
Zydus Lifesciences Ltd. Consolidated 2023-03 2,001.90 904.80 +1.3%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 1,245.23 2,611.70 +0.4%

Bal Pharma Ltd. FAQ's

What is Bal Pharma share price?

Can I buy Bal Pharma shares now?

What is the Dividend Yield of Bal Pharma?

What is the Market Cap of Bal Pharma?

What are the key metrics to analyse Bal Pharma?

What is the 52 Week High and Low of Bal Pharma?

What is the trend of Bal Pharma share price?